Zobrazeno 41 - 50
of 162 694
pro vyhledávání: ''
Autor:
Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Gerald Wulf, Helmut Salih, Michael Lübbert, Michael W. M. Kühn, Thomas Schroeder, Hans Salwender, Katharina Götze, Jörg Westermann, Lars Fransecky, Karin Mayer, Bernd Hertenstein, Mark Ringhoffer, Hans-Joachim Tischler, Sigrid Machherndl-Spandl, Anika Schrade, Peter Paschka, Verena I. Gaidzik, Frauke Theis, Felicitas Thol, Michael Heuser, Richard F. Schlenk, Lars Bullinger, Maral Saadati, Axel Benner, Richard Larson, Richard Stone, Konstanze Döhner, Arnold Ganser
Publikováno v:
Blood Advances. 6:5345-5355
We conducted a single-arm, phase 2 trial (German-Austrian Acute Myeloid Leukemia Study Group [AMLSG] 16-10) to evaluate midostaurin with intensive chemotherapy followed by allogeneic hematopoietic-cell transplantation (HCT) and a 1-year midosta urin
Publikováno v:
Breast Cancer Research and Treatment. 196:67-74
Purpose Elderly patients have different physical condition and tumor biology of breast cancer. Surgical choices for older patients are complicated and several studies have reported that breast conserving surgery (BCS) had better survival than mastect
Autor:
Fangcheng Yuan, Ruth M. Pfeiffer, Sachelly Julián‐Serrano, Simran Arjani, Michael J. Barrett, Jill Koshiol, Rachael Z. Stolzenberg‐Solomon
Publikováno v:
International Journal of Cancer. 152:172-182
Pancreatic cancer (PC) is highly fatal, and its incidence is increasing in the United States. Population-based registry studies suggest associations between a few autoimmune conditions and PC risk, albeit based on a relatively small number of cases.
Autor:
Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y, Ossenkoppele, G J
Publikováno v:
Janssen, J J W M, Löwenberg, B, Manz, M, Biemond, B J, Westerweel, P E, Klein, S K, Fehr, M, Sinnige, H A M, Efthymiou, A, Legdeur, M C J C, Pabst, T, Gregor, M, van der Poel, M W M, Deeren, D, Tick, L W, Jongen-Lavrencic, M, van Obbergh, F, Boersma, R S, de Weerdt, O, Chalandon, Y, Heim, D, Spertini, O, van Sluis, G, Graux, C, Stüssi, G, van Norden, Y & Ossenkoppele, G J 2022, ' Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome ', Leukemia, vol. 36, no. 9, pp. 2189-2195 . https://doi.org/10.1038/s41375-022-01657-3
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Leukemia, 36(9), 2189-2195. Nature Publishing Group
Leukemia, Vol. 36, no.9, p. 2189-2195 (2022)
Leukemia, 36, 2189-2195. Nature Publishing Group
Treatment results of AML in elderly patients are unsatisfactory. In an open label randomized phase II study, we investigated whether addition of the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcome in this population. 102 AML
Autor:
Nirav S, Kapadia, Gabriel A, Brooks, Mary Beth, Landrum, Lauren, Riedel, Pang-Hsiang, Liu, Andrea, Hassol, Amanda S, Tripp, Shalini, Jhatakia, Colleen M, Kummet, Nancy L, Keating
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:39-46
Radiation utilization for breast cancer and metastatic bone disease varies in modality, fractionation, and cost, despite evidence demonstrating equal effectiveness and consensus recommendations such as Choosing Wisely that advocate for higher value c
Autor:
Jacob Hogan, Amit Roy, Patricia Karraker, Jordan R. Pollock, Zachary Griffin, Neha Vapiwala, Jeffrey D. Bradley, Carlos A. Perez, Benjamin W. Fischer-Valuck, John C. Baumann, Brian C. Baumann
Publikováno v:
Int J Radiat Oncol Biol Phys
Radiation oncology (RO) has seen declines in Medicare reimbursement (MCR). However, there are no recent studies analyzing the contributions of specific billing codes to overall RO reimbursement. We compared total MCR for specific Healthcare Common Pr
Autor:
Lalit Kumar, Mohammad Mir Hussain, Rajegowda Chethan, Ranjit Kumar Sahoo, Prabhat S. Malik, Om Dutt Sharma, Anisha Mathew, Ankit Jha, Ritu Gupta, Atul Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Soumyaranjan Malik, Ashish Dutt
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e826-e835
Autologous stem cell transplant (ASCT) is a standard therapy for transplant eligible patients of multiple myeloma (MM). To evaluate impact of time to transplant on subsequent outcomes, we analyzed data on consecutive MM patients who received novel ag
Autor:
Amer M. Zeidan, Namita Joshi, Hrishikesh Kale, Wei-Jhih Wang, Shelby Corman, Tehseen Salimi, Robert S. Epstein
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:670-679
Previous analyses using the SEER-Medicare database have reported substantial underutilization of hypomethylating agents (HMAs) among patients with higher-risk myelodysplastic syndromes (MDS), and an association between poor HMA persistence and high e
Autor:
Takahiro Fukushima, Yoshitaka Oyamada, Shinnosuke Ikemura, Shigenari Nukaga, Takashi Inoue, Daisuke Arai, Keiko Ohgino, Aoi Kuroda, Kota Ishioka, Fumio Sakamaki, Yusuke Suzuki, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima
Publikováno v:
Clinical Lung Cancer. 23:532-541
The optimal treatment for advanced non-small cell lung cancer (NSCLC) in very elderly patients is unclear. We aimed to evaluate their treatment in real-world clinical practice and identify suitable therapy that can improve their prognosis.The medical
Autor:
Taro Yoneda, Takashi Sone, Hayato Koba, Kazuhiko Shibata, Junya Suzuki, Mayuko Tani, Masaru Nishitsuji, Koichi Nishi, Takafumi Kobayashi, Hiroki Shirasaki, Tomoyuki Araya, Toshiyuki Kita, Kazumasa Kase, Kenta Yamamura, Nanao Terada, Shingo Nishikawa, Yuichi Tambo, Hideharu Kimura, Kazuo Kasahara
Publikováno v:
Clinical Lung Cancer. 23:467-476
Immune checkpoint inhibitor (ICI) monotherapy is more effective than cytotoxic chemotherapy in improving overall survival (OS) among patients with advanced-stage non-small cell lung cancer (NSCLC). Recently, chemotherapy combined with ICI has been fo